{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:20:17Z","timestamp":1789968017380,"version":"4.0.1"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"69","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,26]]},"DOI":"10.18632\/oncotarget.23040","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T19:17:27Z","timestamp":1512760647000},"page":"113895-113909","source":"Crossref","is-referenced-by-count":16,"title":["A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment"],"prefix":"10.18632","volume":"8","author":[{"given":"Aradhana","family":"Awasthi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine C.M.","family":"Rolland","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ayello","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmella","family":"van de Ven","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesha","family":"Basrur","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Conlon","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Fermin","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo S.J.","family":"Elenitoba-Johnson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York Medical College, Valhalla, NY, USA"},{"name":"Department of Medicine, New York Medical College, Valhalla, NY, USA"},{"name":"Department of Pathology, New York Medical College, Valhalla, NY, USA"},{"name":"Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA"},{"name":"Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"e82742","DOI":"10.1371\/journal.pone.0082742","article-title":"Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma","volume":"8","author":"Press","year":"2013","journal-title":"PLoS One"},{"key":"2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Patte","year":"2012","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2008.07393.x","article-title":"Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science","volume":"144","author":"Cairo","year":"2009","journal-title":"Br J Haematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dumontet","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"5","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Pui","year":"2006","journal-title":"Blood"},{"key":"6","first-page":"314","article-title":"B-Cell non-Hodgkin\u2019s lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children\u2019s cancer group report","volume":"1","author":"Cairo","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Lindstrom","year":"2011","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Cartron","year":"2012","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results","volume":"27","author":"Goldenberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1002\/cncr.25280","article-title":"Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent\/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) and Groupe Ouest Est des Leuc\u00e9mies et Autres Maladies du Sang (GOELAMS)","volume":"116","author":"Lamy","year":"2010","journal-title":"Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Mendila","year":"2010","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Leonard","year":"2008","journal-title":"N Engl J Med"},{"key":"13","first-page":"113","article-title":"Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma","volume":"13","author":"Cairo","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Cragg","year":"2010","journal-title":"Haematologica"},{"key":"16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Smith","year":"2005","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"Lister","year":"1998","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Shpilberg","year":"2006","journal-title":"Lancet Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1586\/ehm.13.6","article-title":"The current status and future impact of targeted therapies in non-Hodgkin lymphoma","volume":"6","author":"Cheson","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.12434","article-title":"Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma\/leukaemia: a Children\u2019s Oncology Group report","volume":"162","author":"Cairo","year":"2013","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Cairo","year":"2013","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Cairo","year":"2014","journal-title":"Br J Haematol"},{"key":"23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Czuczman","year":"2012","journal-title":"Br J Haematol"},{"key":"24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Hernandez-Ilizaliturri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","article-title":"Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma","volume":"18","author":"Czuczman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"26","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Levy","year":"1999","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Vitolo","year":"2013","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Johnson","year":"2010","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"J\u00e4ger","year":"2010","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Golay","year":"2011","journal-title":"J Immunol"},{"key":"31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13764","article-title":"Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL","volume":"171","author":"Cairo","year":"2015","journal-title":"Br J Haematol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Samoylova","year":"2014","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2014.10.017","article-title":"Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma","volume":"51","author":"Cairo","year":"2015","journal-title":"Eur J Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2013-01-482026","article-title":"Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma","volume":"122","author":"Hogaboam","year":"2013","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ajpath.2014.01.036","article-title":"Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas","volume":"184","author":"Elenitoba-Johnson","year":"2014","journal-title":"Am J Pathol"},{"key":"36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.leukres.2007.07.012","article-title":"Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma","volume":"32","author":"Lim","year":"2008","journal-title":"Leuk Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","article-title":"Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions","volume":"15","author":"Bonavida","year":"2009","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/gb-2013-14-4-r37","article-title":"Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors","volume":"14","author":"Cutillas","year":"2013","journal-title":"Genome Biol"},{"key":"39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/ni.2685","article-title":"Nck-mediated recruitment of BCAP to the BCR regulates the PI(3)K-Akt pathway in B cells","volume":"14","author":"Batista","year":"2013","journal-title":"Nat Immunol"},{"key":"40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.12878","article-title":"Development of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib for B cell malignancies","volume":"1358","author":"Zhuang","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/1061186X.2015.1086357","article-title":"Ibrutinib-A double-edge sword in cancer and autoimmune disorders","volume":"24","author":"Hojjat-Farsangi","year":"2016","journal-title":"J Drug Target"},{"key":"43","first-page":"39","article-title":"Adherence to Ibrutinib Therapy Improves Outcomes in Patients with CLL","volume":"8","author":"Morgan","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"44","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling","volume":"283","author":"Cragg","year":"2008","journal-title":"J Biol Chem"},{"key":"45","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins","volume":"283","author":"Deans","year":"2008","journal-title":"J Biol Chem"},{"key":"46","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/bcj.2013.32","article-title":"Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model","volume":"3","author":"Savina","year":"2013","journal-title":"Blood Cancer J"},{"key":"47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jat.1397","article-title":"The role of p44\/42 activation in tributyltin-induced inhibition of human natural killer cells: effects of MEK inhibitors","volume":"29","author":"Whalen","year":"2009","journal-title":"J Appl Toxicol"},{"key":"48","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumaband in xenograft models","volume":"12","author":"Gerdes","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cellsand in NSG mice","volume":"3","author":"Cairo","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T17:32:27Z","timestamp":1594834347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,9]]},"references-count":49,"journal-issue":{"issue":"69","published-print":{"date-parts":[[2017,12,26]]}},"alternative-id":["23040","29371955"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23040","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,9]]}}}